pdf

O’Melveny Advises Simcere in its US$461 million Hong Kong IPO

October 27, 2020

 

FOR IMMEDIATE RELEASE

HONG KONG—October 27, 2020—O’Melveny advised Simcere Pharmaceutical Group Limited (“Simcere”) in its recent IPO and listing on the Hong Kong Stock Exchange. The IPO offering size was approximately HK$3.57 billion (US$461 million), prior to the exercise of the over-allotment option. Assuming full exercise of the over-allotment option, the offering size will be approximately HK$4.11billion (US$530 million).

Simcere is a company engaged in the R&D, production and commercialization of pharmaceuticals that currently is primarily focused on generic pharmaceuticals. It has a diversified product portfolio in areas of oncology, central nervous system diseases and autoimmune diseases. Simcere, being the first pharmaceutical company with both biologics and small molecule drugs in China listed on the NYSE, was listed on the NYSE from 2007 to 2013.

The O’Melveny team was led by partners Ke Geng and Ke Zhu, and included counsel Yiming Liu and Qianyu Hu, legal consultant Jenny Wang. Valuable support was provided by the San Francisco, Los Angeles, Silicon Valley and New York offices.

Morgan Stanley and CICC were the Joint Sponsors and the leading underwriters. The other underwriters also include UBS, CMB and CNCB. O’Melveny acted as the issuer’s legal adviser as to United States law. William Ji & Co. LLP (in Association with Tian Yuan Law Firm Hong Kong Office) was the issuer’s legal adviser on Hong Kong law. Tian Yuan Law Firm Hong Kong Office was the issuer’s legal adviser on PRC law.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contact:

Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com

Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com